Keiichi Fujiwara

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata et al. · New England Journal of Medicine · 2019 · 2K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

Robert L. Coleman, Mark F. Brady, Thomas J. Herzog et al. · The Lancet Oncology · 2017 · 602 citations · Full text

Medicine, Gynecology, Oncology +15

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)

Andreas du Bois, Michael Quinn, Tate Thigpen et al. · Annals of Oncology · 2005 · 466 citations

Medicine, Gynecology, Oncology +17

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

Éric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 405 citations · Full text

Medicine, Gynecology, Oncology +13